Drug-induced liver injury: Towards early prediction and risk stratification

World Journal of Hepatology

Volumn 9, Issue 1, 2017, Pages 30-37

  Raschi, Emanuel ^a   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hepatotoxicity; Predictivity; Risk assessment; Safety

Indexed keywords

EID: 85009288338     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v9.i1.30     Document Type: Short Survey

References (59)

1. Sarges P, Steinberg JM, Lewis JH. Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. Drug Saf 2016; 39: 801-821 [PMID: 27142208 DOI: 10.1007/s40264-016-0427-8]
2. Lewis JH. The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond. Clin Gastroenterol Hepatol 2015; 13: 2173-2189.e8 [PMID: 26116527 DOI: 10.1016/j.cgh.2015.06.017]
3. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med 2016; 14: 10 [PMID: 26843061 DOI: 10.1186/s12916-016-0553-2]
4. Andrade RJ, Ortega-Alonso A, Lucena MI. "Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge". Expert Opin Drug Metab Toxicol 2016; 12: 589-593 [PMID: 26820043 DOI: 10.1517/17425255.201 6.1141896]
5. García-Cortés M, Robles-Díaz M, Ortega-Alonso A, Medina-Caliz I, Andrade RJ. Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. Int J Mol Sci 2016; 17: 537 [PMID: 27070596 DOI: 10.3390/ijms17040537]
6. Avigan MI, Mozersky RP, Seeff LB. Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States. Int J Mol Sci 2016; 17: 331 [PMID: 26950122 DOI: 10.3390/ijms17030331]
7. Navarro VJ, Barnhart H, Bonkovsky HL, Davern T, Fontana RJ, Grant L, Reddy KR, Seeff LB, Serrano J, Sherker AH, Stolz A, Talwalkar J, Vega M, Vuppalanchi R. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014; 60: 1399-1408 [PMID: 25043597 DOI: 10.1002/hep.27317]
8. Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Cáliz I, González-Jimenez A, Ulzurrun E, Gonzalez AF, Fernandez MC, Romero-Gómez M, Jimenez-Perez M, Bruguera M, Prieto M, Bessone F, Hernandez N, Arrese M, Andrade RJ. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014; 147: 109-118.e5 [PMID: 24704526 DOI: 10.1053/j.gastro.2014.03.050]
9. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-1352.e7 [PMID: 25754159 DOI: 10.1053/j.gastro.2015.03.006]
10. Raschi E, Poluzzi E, Koci A, Caraceni P, De Ponti F. Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol 2014; 6: 601-612 [PMID: 25232453 DOI: 10.4254/wjh. v6.i8.60]
11. Björnsson ES. Hepatotoxicity by Drugs: The Most Common Implicated Agents. Int J Mol Sci 2016; 17: 224 [PMID: 26861310 DOI: 10.3390/ijms17020224]
12. Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol 2015; 89: 327-334 [PMID: 25618544 DOI: 10.1007/s00204-015-1456-2]
13. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80 [PMID: 15206996 DOI: 10.1111/j.1365-2125.2004.02133.x]
14. Bjornsson ES, Jacobsen EI, Einarsdottir R, Chalasani N. Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications. Gastroenterology 2015; 148: 269-273 [PMID: 25527971 DOI: 10.1053/j.gastro.2014.12.007]
15. Agarwal VK, McHutchison JG, Hoofnagle JH. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-470 [PMID: 20170750 DOI: 10.1016/j.cgh. 2010.02.008]
16. Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci 2015; 17: pii: E14 [PMID: 26712744 DOI: 10.3390/ijms17010014]
17. Lo Re V, Haynes K, Forde KA, Goldberg DS, Lewis JD, Carbonari DM, Leidl KB, Reddy KR, Nezamzadeh MS, Roy J, Sha D, Marks AR, De Boer J, Schneider JL, Strom BL, Corley DA. Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model. Clin Gastroenterol Hepatol 2015; 13: 2360-2368 [PMID: 26122767 DOI: 10.1016/j.cgh.2015.06.020]
18. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 2011; 16: 697-703 [PMID: 21624500 DOI: 10.1016/j.drudis.2011.05.007]
19. Stockbridge N, Morganroth J, Shah RR, Garnett C. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf 2013; 36: 167-182 [PMID: 23417505 DOI: 10.1007/s40264-013-0016-z]
20. Nicoletti P, Werk AN, Sawle A, Shen Y, Urban TJ, Coulthard SA, Bjornsson ES, Cascorbi I, Floratos A, Stammschulte T, Gundert-Remy U, Nelson MR, Aithal GP, Daly AK. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtineinduced liver injury. Pharmacogenet Genomics 2016; 26: 218-224 [PMID: 26959717 DOI: 10.1097/FPC.0000000000000209]
21. Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int 2015; 35: 1801-1808 [PMID: 25809692 DOI: 10.1111/liv.12836]
22. Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety-false dawn or new horizon? Expert Opin Drug Saf 2016; 15: 625-634 [PMID: 26923482 DOI: 10.1517/14740338.2016.1160057]
23. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013; 58: 388-396 [PMID: 23258593 DOI: 10.1002/hep.26208]
24. Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 2014; 60: 1015-1022 [PMID: 24799086 DOI: 10.1002/hep.27206]
25. Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, Brouwer KL. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 2014; 42: 665-674 [PMID: 24154606 DOI: 10.1124/dmd.113.054304]
26. König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 2013; 65: 944-966 [PMID: 23686349 DOI: 10.1124/pr.113.007518]
27. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008; 105: 97-105 [PMID: 18524759 DOI: 10.1093/toxsci/kfn109]
28. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, Hunt CM, Freston JW. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2010; 33: 503-522 [PMID: 20486732 DOI: 10.2165/11535340-000 000000-00000]
29. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol 2010; 23: 1215-1222 [PMID: 20553011 DOI: 10.1021/tx1000865]
30. Sakatis MZ, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for & gt; 200 compounds. Chem Res Toxicol 2012; 25: 2067-2082 [PMID: 22931300 DOI: 10.1021/tx300075j]
31. Zhu X, Kruhlak NL. Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using postmarket safety data. Toxicology 2014; 321: 62-72 [PMID: 24721472 DOI: 10.1016/j.tox.2014.03.009]
32. Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016; 21: 648-653 [PMID: 26948801 DOI: 10.1016/j.drudis.2016.02.015]
33. Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, Tong W. Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomark Med 2014; 8: 201-213 [PMID: 24521015 DOI: 10.2217/bmm.13.146]
34. Chen M, Borlak J, Tong W. A Model to predict severity of druginduced liver injury in humans. Hepatology 2016; 64: 931-940 [PMID: 27302180 DOI: 10.1002/hep.28678]
35. Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology 2016; 63: 590-603 [PMID: 26517184 DOI: 10.1002/hep.28323]
36. Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury. J Hepatol 2014; 61: 293-300 [PMID: 24681117 DOI: 10.1016/j.jhep.2014.03.026]
37. Liakoni E, Rätz Bravo AE, Krähenbühl S. Hepatotoxicity of New Oral Anticoagulants (NOACs). Drug Saf 2015; 38: 711-720 [PMID: 26138527 DOI: 10.1007/s40264-015-0317-5]
38. Raschi E, De Ponti F. Drug-and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World J Hepatol 2015; 7: 1761-1771 [PMID: 26167249 DOI: 10.4254/wjh.v7.i13.1761]
39. Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, Moretti U, Moore N, De Ponti F. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol 2015; 80: 285-293 [PMID: 25689417 DOI: 10.1111/bcp.12611]
40. Raschi E, Bianchin M, Ageno W, De Ponti R, De Ponti F. Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications. Pol Arch Med Wewn 2016; 126: 552-561 [PMID: 27578223 DOI: 10.20452/pamw.3529]
41. Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, Knabb RM, Frost C, Schuster A, Hao F, Gu Z, Humphreys WG, Grossman SJ. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 2009; 37: 1738-1748 [PMID: 19420130 DOI: 10.1124/dmd.108.025981]
42. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056-1064 [PMID: 19196845 DOI: 10.1124/dmd.108.025569]
43. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295 [PMID: 18399711 DOI: 10.216 5/00003088-200847050-00001]
44. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 1998; 21: 1029-1034 [PMID: 9604234 DOI: 10.1111/j.1540-8159.1998.tb00148.x]
45. Chan NC, Eikelboom JW, Weitz JI. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. Circ Res 2016; 118: 1409-1424 [PMID: 27126650 DOI: 10.1161/CIRCRESAHA.116.306925]
46. Jiang J, Wolters JE, van Breda SG, Kleinjans JC, de Kok TM. Development of novel tools for the in vitro investigation of druginduced liver injury. Expert Opin Drug Metab Toxicol 2015; 11: 1523-1537 [PMID: 26155718 DOI: 10.1517/17425255.2015.1065 814]
47. Gómez-Lechón MJ, Tolosa L. Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening. Arch Toxicol 2016; 90: 2049-2061 [PMID: 27325232 DOI: 10.1007/s00204-016-1756-1]
48. Raschi E, De Ponti F. Drug Utilization Research and Pharmacovigilance. In: Elseviers M, Wettermark B, Almarsdóttir AB, Andersen M, Benko R, Bennie M, Eriksson I, Godman B, Krska J, Poluzzi E, Taxis K, Vlahovic-Palcevski V, Vander Stichele R. Drug Utilization Research: Methods and Applications. Chichester UK: John Wiley & Sons, 2016: 399-407
49. Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 2014; 348: g2366 [PMID: 24736555 DOI: 10.1136/bmj.g2366]
50. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121: 1047-1060 [PMID: 20142454 DOI: 10.1161/CIRCULATIONAHA.109.192704]
51. Behr ER, January C, Schulze-Bahr E, Grace AA, Kääb S, Fiszman M, Gathers S, Buckman S, Youssef A, Pirmohamed M, Roden D. The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. Eur Heart J 2013; 34: 1958-1963 [PMID: 22752616 DOI: 10.1093/eurheartj/ehs172]
52. Thomas SH, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol 2016; 81: 420-427 [PMID: 26183037 DOI: 10.1111/bcp.12726]
53. Schwartz PJ, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol 2016; 67: 1639-1650 [PMID: 27150690 DOI: 10.1016/j.jacc.2015.12.063]
54. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303 [PMID: 17506785 DOI: 10.1111/j.1365-2125.2007.02899.x]
55. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880 [PMID: 16328318 DOI: 10.1007/s00228-005-0043-5]
56. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74-81 [PMID: 18832478 DOI: 10.1124/dmd.108.023143]
57. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743-753 [PMID: 20081065 DOI: 10.1177/0091270009351883]
58. Kalgutkar AS, Dalvie D. Predicting toxicities of reactive metabolite-positive drug candidates. Annu Rev Pharmacol Toxicol 2015; 55: 35-54 [PMID: 25292426 DOI: 10.1146/annurev-pharmtox-010814-124720]
59. Liu R, Yu X, Wallqvist A. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J Cheminform 2015; 7: 4 [PMID: 25717346 DOI: 10.1186/s13321-015-0053-y]